Status:

COMPLETED

Cartography and Quantitative Characterization of Achilles Tendon Fibrocartilage by TE = 0ms Imaging at 3T MRI

Lead Sponsor:

University Hospital, Bordeaux

Collaborating Sponsors:

General Electric

Conditions:

Spondyloarthropathy

Tendinopathy

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to accurately map calcaneal fibrocartilage using TE = 0 ms imaging, and then apply measurements of our control population to SpA patients with peripheral enthesis study us...

Detailed Description

The human body contains a lot of tissue components with short T2 (transversal relaxation time) that are not or only poorly detected on conventional T2-weighted MR sequences. These components are mostl...

Eligibility Criteria

Inclusion

  • Age ≥18 years,
  • Covered under social security
  • Informed signed consent
  • Additional criteria for each group:
  • GROUP 1: HEALTHY VOLUNTEERS
  • Absence of diagnosis of spondyloarthropathies
  • No previous history of plantar support and pain, calcaneal tendinopathy, infiltration or surgery
  • GROUP 2: SPA + NON-SYMPTOMATICS AT THE CALCANEEN FIBROCARTILAGE LEVEL
  • ASAS criteria axial or appendicular
  • No previous history of plantar support and pain, infiltration or surgery
  • Prescription Achile's tendon MRI with injection of contrast agent (macrocyclic gadolinium) in usual care.
  • GROUP 3: SPA + SYMPTOMATICS AT THE CALCANEEN FIBROCARTILAGE LEVEL
  • ASAS criteria axial or appendicular
  • Clinical suspicion of rheumatic enthesopathy
  • Absence of a history of calcaneal infiltration or surgery
  • Prescription Achile's tendon MRI with injection of contrast agent (macrocyclic gadolinium) in usual care.
  • GROUP 4: MECHANIC TENDINOPATHY
  • Clinical diagnosis of calcaneal mechanical tendinopathy
  • Absence of diagnosis of spondyloarthropathies
  • No any previous history of plantar support disorder, calcaneal infiltration or surgery
  • Prescription Achile's tendon MRI with injection of contrast agent (macrocyclic gadolinium) in usual care.

Exclusion

  • Age less than 18 yrs old
  • Pregnant or lactating woman
  • History or presence coronary pathology
  • Septic arthritis
  • Immunodeficiency.
  • Contra-indication for MRI exam
  • Legal protection
  • Additional criteria for GROUPS 2, 3 and 4:
  • History or presence of renal insufficiency
  • Allergy to macrocyclic gadolinium

Key Trial Info

Start Date :

April 7 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 21 2023

Estimated Enrollment :

121 Patients enrolled

Trial Details

Trial ID

NCT03287596

Start Date

April 7 2018

End Date

January 21 2023

Last Update

February 22 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHU de Bordeaux

Bordeaux, France, 33076